Corporate News: Bonesupport Holding AB
Bonesupport (BONEX.ST) experienced a modest upward movement of 1.26 % during the 24‑hour period concluding at 21:28 Central European Time on Friday, 23 March 2026. At the close, the stock traded at approximately SEK 332.6 on major exchanges, reflecting a market capitalization of roughly SEK 1.6 billion. Over the past 24 hours, trading volume reached SEK 109.7 million, while the total outstanding shares numbered 65.9 million. Since the end of last month, the share price has appreciated by 20.07 %.
The 200‑day simple moving average sits at SEK 215.9, signalling a bullish trend. Historically, the share’s highest price over the past 52 weeks was SEK 273.2, reached on 17 April 2026, whereas the 52‑week low was SEK 165 on 24 February 2026.
Third‑Quarter 2026 Interim Report Highlights
In its most recent quarterly communication, Bonesupport Holding AB disclosed a robust growth trajectory across multiple geographies. Revenue increased markedly, with the United States segment exhibiting the strongest momentum, followed by solid expansion in European and other international markets. Gross and adjusted operating margins remained healthy, and earnings per share rose appreciably relative to the preceding period.
Management underscored significant progress in clinical evidence, regulatory approvals, and commercialization activities. The flagship product, CERAMENT G, continued to gain market penetration, while the pipeline product CERAMENT V advanced through development milestones. These developments reinforce the company’s position as a leader in bio‑ceramic composites and bone graft substitutes.
In a move aimed at bolstering shareholder value, the board approved a share‑buyback program. Several hundred thousand shares were repurchased during the reporting period, tightening the equity base and potentially enhancing earnings per share. Analysts have responded by raising their price targets, citing the sustained growth trajectory and the strengthening market position of the product portfolio.
Comparative Performance of Peer Stocks
| Stock | 24‑hr Change | Current Price | Market Cap | P/E Ratio | Recent Highlights |
|---|---|---|---|---|---|
| Granges (GRNG.ST) | –1.04 % | SEK 167.9 | SEK 1.7 bn | 15.22 | Sales remain stable; modest revenue growth. |
| Studsvik (SVIK.ST) | +2.12 % | SEK 200.5 | SEK 1.8 bn | 58.43 | Positive operating result Q3 2026; net loss; expansion into Fukushima nuclear market via partnership with ReNu Industries. |
| Vimian (VIMIAN.ST) | 0 % | SEK 40.9 | SEK 1.9 bn | 49.18 | Slight earnings rise; EBITDA €29 m; analysts raise target; upcoming Capital Markets Day in November. |
| Carasent (CARA.ST) | +4.21 % | SEK 27.0 | SEK 1.9 bn | — | Stronger market share in the European dental implant segment; no P/E disclosed. |
The peer analysis illustrates a mixed landscape: while Granges and Vimian exhibit stability, Studsvik and Carasent have posted gains, reflecting divergent industry dynamics and strategic focus.
Company Overview
Bonesupport Holding AB is a specialty pharmaceutical firm dedicated to the development and distribution of bio‑ceramic composites, bone graft substitutes, and related healthcare products. The company’s portfolio addresses a broad spectrum of orthopedic and reconstructive needs, positioning it as a key player in the global medical device and biomaterials market.